Genentech, a member of the Roche Group (RHHBY), said that its novel anti-TIGIT Tiragolumab has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, in combination with Tecentriq for the first-line treatment of people with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression with no EGFR or ALK genomic tumor aberrations.
Genentech noted that Tiragolumab is the first anti-TIGIT therapy to be granted Breakthrough Therapy Designation and marks the 37th BTD for Genentech's portfolio of medicines.
The breakthrough therapy designation was based on the randomized Phase II CITYSCAPE study that showed encouraging efficacy and safety with tiragolumab plus Tecentriq or atezolizumab in people with PD-L1-positive metastatic non-small cell lung cancer.
The company noted that broad tiragolumab development program is ongoing across various settings in different tumor types, including lung, esophageal and cervical cancers.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.